Kidswell Bio Corporation
Research Kidswell Bio Corporation (4584.T) on Bullrun: market cap JPY 7.79B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4584.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 7.79B
- Financial periodFY2026
- RevenueJPY 6.59B
- Revenue growth29.7%
- Net income-JPY 413.99M
- Free cash flow-JPY 1.11B
- Gross margin26.5%
Valuation Snapshot
latest market cap is JPY 7.79B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 6.59B | -JPY 413.99M | -JPY 1.11B | 26.5% | -8.48 | JPY 3.29B | JPY 2.55B | JPY 1.65B |
| FY2025 | JPY 5.08B | -JPY 21.14M | JPY 930.26M | 32.3% | -0.52 | JPY 3.00B | JPY 1.84B | JPY 1.41B |
| FY2024 | JPY 2.43B | -JPY 1.42B | -JPY 453.63M | 42.8% | -40.23 | JPY 2.23B | JPY 2.58B | JPY 831.47M |
| FY2023 | JPY 2.78B | -JPY 657.43M | -JPY 1.42B | 55.0% | -20.77 | JPY 1.07B | JPY 1.95B | JPY 1.23B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 7.79B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Kidswell Bio Corporation
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kidswell Bio Corporation's market cap?
Kidswell Bio Corporation's market capitalization is JPY 7.79B.
What does Kidswell Bio Corporation do?
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd.